New modalities give HER3 another shot at ASCO

HER2 is the focus of the most highly anticipated readouts at this year’s ASCO meeting, but related target HER3 is also having a moment as new modalities breathe life to the historically challenging target.

At the American Society of Clinical Oncology (ASCO) conference, Daiichi Sankyo Co. Ltd. (Tokyo:4568) and Merus N.V. (NASDAQ:MRUS) will present early clinical data suggesting HER3-targeted new-modality therapies may be effective in indications with few treatment options including HR-positive, HER2-negative breast cancer — an indication already in the ASCO spotlight as antibody-drug conjugates against other targets face off with Phase III data...